Qiagen Partners with Pathway Diagnostics, Sequenom on Dx, Biomarker Discovery | GenomeWeb
NEW YORK (GenomeWeb News) - Qiagen has agreed to a new marketing partnership with Pathway Diagnostics and has entered into a research agreement with Sequenom, the company said today.
 
Under the agreement with Malibu, Calif.-based Pathway, Qiagen said the companies will offer customers a bundled solution of Qiagen's assays and Pathway's clinical development and testing services, Qiagen said. Qiagen said it will use its sales force to "develop project opportunities" for the companies to address jointly.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.